Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in Severe Pneumonia
NCT07338123Phase 1Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Oncolytic Viruses, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Yiqi Huoxue Jiedu formula and bacteriophages in pneumonia (4 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Clearance rate of drug-resistant bacteria at 14 days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Yiqi Huoxue Jiedu formulabacteriophages
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT07338123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338123.